MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1136/jitc-2021-004001

Медицинская библиотека · Journal for immunotherapy of cancer · 2022

Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers.

Fucà Giovanni, Cohen Romain, Lonardi Sara, Shitara Kohei, Elez Maria Elena, Fakih Marwan, Chao Joseph, Klempner Samuel J, Emmett Matthew, Jayachandran Priya, Bergamo Francesca, García Marc Díez, Mazzoli Giacomo, Provenzano Leonardo, Colle Raphael, Svrcek Magali, Ambrosini Margherita, Randon Giovanni, Shah Aakash Tushar, Salati Massimiliano, Fenocchio Elisabetta, Salvatore Lisa, Chida Keigo, Kawazoe Akihito, Conca Veronica, Curigliano Giuseppe, Corti Francesca, Cremolini Chiara, Overman Michael, Andre Thierry, Pietrantonio Filippo

СтатьяМногоцентровое исследованиеПеревод в очереди

Аннотация

BACKGROUND

Despite unprecedented benefit from immune checkpoint inhibitors (ICIs) in patients with mismatch repair deficient (dMMR)/microsatellite instability high (MSI-H) advanced gastrointestinal cancers, a relevant proportion of patients shows primary resistance or short-term disease control. Since malignant effusions represent an immune-suppressed niche, we investigated whether peritoneal involvement with or without ascites is a poor prognostic factor in patients with dMMR/MSI-H metastatic colorectal cancer (mCRC) and gastric cancer (mGC) receiving ICIs.

METHODS

We conducted a global multicohort study at Tertiary Cancer Centers and collected clinic-pathological data from a cohort of patients with dMMR/MSI-H mCRC treated with anti-PD-(L)1 ±anti-CTLA-4 agents at 12 institutions (developing set). A cohort of patients with dMMR/MSI-high mGC treated with anti-PD-1 agents±chemotherapy at five institutions was used as validating dataset.

RESULTS

The mCRC cohort included 502 patients. After a median follow-up of 31.2 months, patients without peritoneal metastases and those with peritoneal metastases and no ascites had similar outcomes (adjusted HR (aHR) 1.15, 95% CI 0.85 to 1.56 for progression-free survival (PFS); aHR 0.96, 95% CI 0.65 to 1.42 for overall survival (OS)), whereas inferior outcomes were observed in patients with peritoneal metastases and ascites (aHR 2.90, 95% CI 1.70 to 4.94; aHR 3.33, 95% CI 1.88 to 5.91) compared with patients without peritoneal involvement. The mGC cohort included 59 patients. After a median follow-up of 17.4 months, inferior PFS and OS were reported in patients with peritoneal metastases and ascites (aHR 3.83, 95% CI 1.68 to 8.72; aHR 3.44, 95% CI 1.39 to 8.53, respectively), but not in patients with only peritoneal metastases (aHR 1.87, 95% CI 0.64 to 5.46; aHR 2.15, 95% CI 0.64 to 7.27) when compared with patients without peritoneal involvement.

CONCLUSIONS

Patients with dMMR/MSI-H gastrointestinal cancers with peritoneal metastases and ascites should be considered as a peculiar subgroup with highly unfavorable outcomes to current ICI-based therapies. Novel strategies to target the immune-suppressive niche in malignant effusions should be investigated, as well as next-generation ICIs or intraperitoneal approaches.

Для цитирования: Fucà Giovanni, Cohen Romain, Lonardi Sara, Shitara Kohei, Elez Maria Elena, Fakih Marwan, Chao Joseph, Klempner Samuel J, Emmett Matthew, Jayachandran Priya, Bergamo Francesca, García Marc Díez, Mazzoli Giacomo, Provenzano Leonardo, Colle Raphael, Svrcek Magali, Ambrosini Margherita, Randon Giovanni, Shah Aakash Tushar, Salati Massimiliano, Fenocchio Elisabetta, Salvatore Lisa, Chida Keigo, Kawazoe Akihito, Conca Veronica, Curigliano Giuseppe, Corti Francesca, Cremolini Chiara, Overman Michael, Andre Thierry, Pietrantonio Filippo. Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers.. Journal for immunotherapy of cancer. 2022. DOI: 10.1136/jitc-2021-004001.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.